BioSpace News Archive

BioSpace Global Roundup, April 2

Biopharma companies from across the globe provide updates on their pipelines and business practices.

April 1, 2020
·
5 min read
·
Alex Keown
Business

Modalis Obtains Access to Foundational CRISPR IP

Modalis Therapeutics Corporation announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intellectual property that is controlled by Editas Medicine.

April 1, 2020
·
2 min read
Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19

The biopharmaceutical group Ipsen has answered call of the Institut Pasteur and announces a donation of €2 million dedicated to COVID-19 research.

April 1, 2020
·
3 min read
Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19

Neurimmune AG and Ethris GmbH announced an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19.

April 1, 2020
·
4 min read
Deals

Calliditas Strengthens its US Commercial Organization

Calliditas Therapeutics AB announced it has strengthened its operations in the United States with the addition of Christopher Ngai as Vice President, US Market Access.

April 1, 2020
·
2 min read
Alligator Bioscience Informs About Temporary Halt of Recruitment of New Patients due to the COVID-19 Pandemic

Alligator Bioscience, announced a temporary halt in the recruitment of new patients to the company’s ongoing Phase I clinical trials with the drug candidates ATOR-1015 and ATOR-1017.

April 1, 2020
·
4 min read
EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study

EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, announced initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO Study,1 based on a pre-planned data analysis on 24 March 2020.

April 1, 2020
·
9 min read
Business

Molina Healthcare Announces First Quarter 2020 Earnings Release and Conference Call Dates

Molina Healthcare, Inc. announced details for the release of its results for the first quarter ended March 31, 2020.

April 1, 2020
·
1 min read
Policy

FDA accepts Besoblast’s Biologics Licence application for RYONCIL™ and agrees to priority review

Mesoblast Limited announced that the United States Food and Drug Administration has accepted for priority review the Company’s Biologics License Application filing for RYONCILTM, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease.

April 1, 2020
·
6 min read
MolecuLight Announces Industry Partnership and Virtual Exhibit of its MolecuLight i:X® Platform at WoundCon™ 2020, the Largest Conference for Wound Care

Novel Virtual Conference Attracts 10,000 Wound Care Professionals as Alternate to Live Medical Conferences Given Travel Challenges Due to Covid-19

April 1, 2020
·
3 min read